MedTrace Logo

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

NCT02121717 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 535

Last updated 2019-10-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.

Conditions

Interventions

DRUG

Chiglitazar

Take orally

DRUG

Placebo

Take orally

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Linong Ji, Dr. · Peking University People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02121717 on ClinicalTrials.gov